NFKB1 and metabolic dysfunction-associated steatotic liver disease: In conclusion, we demonstrated that Foxa2 ameliorates hepatic steatosis in NAFLD and suppresses NF-κB/IKK signaling pathway activation in OA-stimulated HepG2 cells, thus presenting a new therapeutic target for NAFLD treatment.